Long-term survival in metastatic malignant melanoma: Ipilimumab followed by vemurafenib in a patient with brain metastasis

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2819-2823

  Balakan, Ozan ^a   Süner, Ali ^a   Yiǧiter, Remzi ^a   Balakan, Tuba ^b   Şirikçi, Akif ^a   Sevinç, Alper ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Avukat Cengiz Gokcek State Hospital   (Turkey)

Author keywords

Brain; Ipilimumab; Melanoma; Survival; Vemurafenib

Indexed keywords

B RAF KINASE; DACARBAZINE; DEXAMETHASONE; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BRAIN METASTASIS; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DIARRHEA; DRUG DOSE INCREASE; EDEMA; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; LONG TERM SURVIVAL; MALE; MELANOMA METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARALYSIS; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SPEECH DISORDER;

ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; SULFONAMIDES; TIME FACTORS;

EID: 84867822671     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7675     Document Type: Article

References (32)

1. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 21 Suppl 7: vii339-vii344, 2010.
2. Johnson JD, Young B. Demographics of brain metastasis. Neuro-surg Clin N Am 7: 337, 1996.
3. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diag-nosis, treatment and survival. Cancer 42: 660-668, 1978.
4. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16: 248-255, 2009.
5. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201, 1995.
6. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 213: 48-65, 2006.
7. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595, 2009.
8. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of mela-noma and other malignancies. Cancer 110: 2614-2627, 2007.
9. Robert C, Ghiringhelli F. What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metas-tatic melanoma? Oncologist 14: 848-861, 2009.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723, 2010.
11. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacar-bazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526, 2011.
12. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mu-tation in human cancer genomes. Nature 446: 153-158, 2007.
13. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
14. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation pre-dicts sensitivity to MEK inhibition. Nature 439: 358-362, 2006.
15. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibi-tor needs broad target blockade in BRAF-mutant melanoma. Na-ture 467: 596-599, 2010.
16. Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3: 118, 1996.
17. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demograph-ics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88: 11-20, 1998.
18. Fife KM, Colman MH, Stevens GN, et al. Determinants of out-come in melanoma patients with cerebral metastases. J Clin Oncol 22: 1293, 2004.
19. Sawaya R, Bindal RK. Metastatic brain tumors. In: Brain Tumors, Kaye AH, Laws ER Jr, Eds. Churchill Livingstone, New York, 1995: 923.
20. Carlino MS, Atkins MB, Warneke CL, et al. Differences between Australia (OZ) and the United States (US) in the patterns, progno-sis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study (abstract). Society for Melanoma Research 2010.
21. Grob JJ, Regis J, Laurans R, et al. Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J Cancer 34: 1187-1192, 1998.
22. Chiarion-Sileni V, Guida M, Ridolfi L, et al; Italian Melanoma In-tergroup (IMI). Dose-dense temozolomide regimen for the treat-ment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Br J Cancer 104: 1816-1821, 2011. Epub 2011 May 24.
23. Mornex F, Thomas L, Mohr P, et al. Prospective randomized mul-ticentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant mela-noma. Melanoma Res 13: 97-103, 2003.
24. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a novel BRAF Inhibitor: Vemurafenib (PLX4032). J Pharmacol Exp Ther 342: 30-40, 2012.
25. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for mela-noma metastases to the brain. N Engl J Med 365: 2439-2441, 2011.
26. Dummer R, Rinderknecht J, Goldinger SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic mela-noma patients with brain metastases. J Clin Oncol 29: 2011. 2011 ASCO Annual Meeting (suppl; abstr 8548).
27. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, ac-tivated BRAF in metastatic melanoma. N Engl J Med 363: 809-819, 2010.
28. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
29. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK 2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. 2010 ASCO Annual Meeting. J Clin Oncol 28: 15s, 2010 (suppl; abstr 8503).
30. Lawrence DP, Hamid O, McDermott DF, et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metas-tases. J Clin Oncol 28(Suppl; abstract 8523): 15s, 2010.
31. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21: 530-534, 2011.
32. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13: 459-465, 2012 May Epub 2012 Mar 27.